Mechanistically, resistant monocytic AML has a distinct transcriptomic profile with loss of expression of venetoclax’s target, BCL-2, and reliance on MCL-1 to mediate oxidative phosphorylation and survival (Pei et al., 2020). The gene discussed is BCL2; the disease is acute myeloid leukemia.